Nektar Therapeutics (NKTR) EBIT Margin: 2010-2025
Historic EBIT Margin for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -268.63%.
- Nektar Therapeutics' EBIT Margin fell 12627.00% to -268.63% in Q3 2025 from the same period last year, while for Sep 2025 it was -156.69%, marking a year-over-year increase of 764.00%. This contributed to the annual value of -106.88% for FY2024, which is 18571.00% up from last year.
- According to the latest figures from Q3 2025, Nektar Therapeutics' EBIT Margin is -268.63%, which was up 17.14% from -324.21% recorded in Q2 2025.
- Over the past 5 years, Nektar Therapeutics' EBIT Margin peaked at 49.18% during Q4 2024, and registered a low of -708.07% during Q2 2022.
- In the last 3 years, Nektar Therapeutics' EBIT Margin had a median value of -211.90% in 2024 and averaged -244.02%.
- In the last 5 years, Nektar Therapeutics' EBIT Margin crashed by 31,906bps in 2022 and then soared by 46,123bps in 2023.
- Over the past 5 years, Nektar Therapeutics' EBIT Margin (Quarterly) stood at -451.48% in 2021, then spiked by 21,323bps to -238.25% in 2022, then surged by 9,794bps to -140.30% in 2023, then skyrocketed by 18,948bps to 49.18% in 2024, then slumped by 12,627bps to -268.63% in 2025.
- Its last three reported values are -268.63% in Q3 2025, -324.21% for Q2 2025, and -425.76% during Q1 2025.